Helicobacter pylori Seropositivity in Patients with Type 2 Diabetes Mellitus in South-East of Iran
,
Abstract
It has been also reported that that H. pylori infection may be responsible for some endocrine disorders, such as autoimmune thyroid diseases, diabetes mellitus and primary hyperparathyroidism. H. pylori which express cytotoxin-associated gene A (CagA) may be more virulent than those that do not. The aim was to evaluate the seroprevalence of anti-H. pylori IgG and anti-CagA antibodies in patients with type 2 diabetes mellitus (type 2 DM) and healthy individuals from Rafsanjan city (Iran). A total of 100 patients with type 2 diabetes and 100 age-matched healthy individuals were enrolled to study. A blood sample was collected from each participant. The type 2 DM established according to the fasting blood glucose level of 126 mg/dl. The sera were tested for the presence of anti-H. pylori IgG antibodies and antibody to CagA by use of enzyme linked immunosorbent assay. The seroprevalence of anti-H. pylori antibodies in diabetic patients (76%) was similar to that observed in healthy subjects (75%). The mean titer of anti-H. pylori IgG in healthy control group (131.63±11.68 U/ml) was significantly higher than diabetic group (54.43±4.50 U/ml; P<0.0001). The prevalence of serum anti-CagA IgG antibodies was 78.9% in infected diabetic patients and 77.3% in healthy control group with mean titer of 75.02±4.54 U/ml and 84.34±5.85 U/ml, respectively. No significant differences were observed between diabetic and healthy control groups regarding the prevalence and the mean titer of anti-CagA IgG antibodies. In the diabetic group, the seropositive rate of anti-H. pylori IgG was higher in women as compared to men, but the difference was not statistically significant. These results show that H. pylori seropositivity rate was similar in type 2 DM patients and non-diabetics control group. No association was also found between CagA-positive strains of H. pylori and type 2 DM.
Sibony M, Jones NL. Recent advances in Helicobacter pylori pathogenesis. Curr Opin Gastroenterol 2012;28(1):30-5.
Figura N. Identifiable Helicobacter pylori strains or factors important in the development of duodenal ulcer disease.Helicobacter 1997;(2 Suppl 1):S3-12.
Backert S, Clyne M. Pathogenesis of Helicobacter pylori infection. Helicobacter 2011;16 Suppl 1:19-25.
Jafarzadeh A, Rezayati MT, Nemati M. Specific serum immunoglobulin G to H pylori and CagA in healthy children and adults (south-east of Iran). World J Gastroenterol 2007;13(22):3117-21.
Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2011;16 Suppl 1:65-9.
Figura N, Franceschi F, Santucci A, Bernardini G, Gasbarrini G, Gasbarrini A. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 2010;15 Suppl1:60-8.
Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J Gastroenterol 2009;15(22):2701-7.
Haghdoost AA, Rezazadeh-Kermani M, Sadghirad B, Baradaran HR. Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis. East Mediterr Health J 2009;15(3):591-9.
Azimi-Nezhad M, Ghayour-Mobarhan M, Parizadeh MR, Safarian M, Esmaeili H, Parizadeh SM, Khodaee G, Hosseini J, Abasalti Z, Hassankhani B, Ferns G. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. Singapore Med J 2008;49(7):571-6.
Devrajani BR, Shah SZ, Soomro AA, Devrajani T. Type 2 diabetes mellitus: A risk factor for Helicobacter pylori infection: A hospital based case-control study. Int J Diabetes Dev Ctries 2010;30(1):22-6.
Gulcelik NE, Kaya E, Demirbas B, Culha C, Koc G, Ozkaya M, Cakal E, Serter R, Aral Y. Helicobacter pylori prevalence in diabetic patients and its relationship with dyspepsia and autonomic neuropathy. J Endocrinol Invest 2005;28(3):214-7.
Bener A, Micallef R, Afifi M, Derbala M, Al-Mulla HM, Usmani MA. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol 2007;18(4):225-9.
Anastasios R, Goritsas C, Papamihail C, Trigidou R, Garzonis P, Ferti A. Helicobacter pylori infection in diabetic patients: prevalence and endoscopic findings. Eur J Intern Med 2002;13(6):376.
Ciortescu I, Sfarti C, Stan M, Graur M, Stanciu C. (Prevalence of Helicobacter pylori infection in patients with diabetes mellitus). Rev Med Chir Soc Med Nat Iasi 2009;113(4):1048-55.
Xia HH, Talley NJ, Kam EP, Young LJ, Hammer J, Horowitz M. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001;96(4):1039-46.
Quadri, R, Rossi C, Catalfamo E, Masoero G, Lombardo L, Della Monica P, Rovera L, Pera A, Cavello Perin P.Helicobacter pylori infection in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2000;10(5):263-6.
Quatrini M, Rossi C, Catalfamo E, Masoero G, Lombardo L,Della Monica P, Rovera L, Pera A, Cavello Perin P. Helicobacter pylori prevalence in patients with diabetes and its relationship to dyspeptic symptoms. J Clin Gastroenterol2001;32(3):215-7.
Kojecky V, J Roubalik, Bartonikova N. Helicobacter pylori in patients with diabetes mellitus. Vnitr Lek 1993;39(6):581-4.
Cover TL, Glupczynski Y, Lage AP, Burette A, Tummuru MK, Perez-Perez GI, Blaser MJ. Serologic detection of infection with cagA+ Helicobacter pylori strains. J Clin Microbiol 1995;33(6):1496-500.
Jafarzadeh A, Hassanshahi GH, Nemati M. Serum levels of high-sensitivity C-reactive protein (hs-CRP)in Helicobacter pylori-infected peptic ulcer patients and its association with bacterial CagA virulence factor. Dig Dis Sci 2009;54(12):2612-6.
Jafarzadeh A, Esmaeeli-Nadimi A, Nemati M, Tahmasbi M, Ahmadi P. Serum concentrations of Helicobacter pylori IgG and the virulence factor CagA in patients with ischaemic heart disease. East Mediterr Health J 2010;16(10):1039-44.
Jafarzadeh A, Salari M. Seroprevalence of anti-Helicobacter pylori and anti-CagA antibodies in peptic ulcer and healthy subjects in the city of Rafsanjan. J Res Med Sci 2006;11(5):15-22.
Jafarzadeh A, Mirzaee V, Ahmad-Beygi H, Nemati M, Rezayati MT. Association of the CagA status of Helicobacter pylori and serum levels of interleukin (IL)-17 and IL-23 in duodenal ulcer patients. J Dig Dis 2009;10(2):107-12.
Jafarzadeh A, Sajadi M. Evaluation of the serum Interleukin- 18 levels in helicobacter pylori-infected peptic ulcer patients and its association with bacterial CagA virulence factor. Iran J Immunol 2006;3(1):15-22.
Wen S, Velin D, Felley CP, Du L, Michetti P, Pan- Hammarström Q. Expression of Helcobacter pylori virulence factors and associated expression profiles of inflammatory genes in the human gastric mucosa. Infect Immun 2007;75(11):5118-26.
Kim JM, Kim JS, Jung HC, Song IS, Kim CY. Virulence factors of Helicobacter pylori in Korean isolates do not influence proinflammatory cytokine gene expression and apoptosis in human gastric epithelial cells, nor do these factors influence the clinical outcome. J Gastroenterol 2000;35(12):898-906.
Azuma T. Helicobacter pylori CagA protein variation associated with gastric cancer in Asia. J Gastroenterol 2004;39(2):97-103.
Zelenkova J, Soucková A, Kvapil M, Soucek A, Vejvalka J, Segethová J. Helicobacter pylori and diabetes mellitus. Cas Lek Cesk 2002;141(18):575-7.
| Files | ||
| Issue | Vol 51, No 12 (2013) | |
| Section | Original Article(s) | |
| Keywords | ||
| Anti-CagA Helicobacter pylori IgG Type 2 diabetes | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
